Skip to main content

Critical Care Reviews Newsletter

Newsletter 591  |  April 9th, 2023

Please support our work to share science

A Massive Paediatric Trial Results Presentation to be added to the CRR23 Programme Tomorrow

Welcome to the 591st Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

This week we announced two more fantastic trial result presentations for the Critical Care Reviews Meeting 2023. Glenn Eastwood and Alistair Nichol will deliver the results of the TAME cardiac arrest trial, examining targeted therapeutic mild hypercapnia after resuscitated cardiac arrest. Karim Brohi will give the results of the CRYOSTAT-2 trial, evaluating early high-dose cryoprecipitate in adult patients with major traumatic haemorrhage. Tomorrow (Monday, April 10th), we announce our sixth major trial result presentation, this time a massive paediatric trial.

In addition to TAME & CRYOSTAT-2, we are also hosting the results presentations of the first RCT of the REBOA device, the UK REBOA Trial; the 2000 patient American video versus direct laryngoscope trial, DEVICE; and the international PATCH-Trauma trial, examining prehospital tranexamic acid in severe trauma. We'll also review some of the best trials presented over the past year, including AID-ICU (haloperidol for delirium), TEAM (early mobilisation), CLOVERS (early vasopressors in sepsis), PILOT (oxygenation targets) and the 180 day outcomes of the COVID-19 domains of the REMAP-CAP trial. We still have some further trials to add as well as our panel discussions. If you're interested in the evidence that informs our clinical practice, join us in June for the best critical care trials in the world.

Support CCR

You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.

I hope you find this newsletter useful.


Until next week

Rob